Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New outlook for treatment for bile duct cancer
drugs (stock image)
"We are excited by these results because these drugs are already being tested in clinical trials for other types of cancer and could be beneficial for patients with cholangiocarcinoma.”
Scientists testing experimental drugs that target a key tumour growth pathway

Those with cancer of the bile duct could soon be helped by a new class of experimental drug, a study led by the University of Edinburgh has revealed.

Scientists have discovered that a key pathway, known as wnt, is the driving force behind the growth of tumours in bile duct cancer.

Experimental drugs that block the wnt pathway are already being tested in patients with other cancers, but this is the first sign that bile duct cancer could also be treated in this way.

Researchers discovered that the treatment stopped the bile duct cancer cells from growing in the lab and shrank tumours in animals with the disease. They are now preparing to test whether these drugs will be effective in human patients.

The bile ducts are a series of tubes that drain toxins from the liver. Bile duct cancer, known as cholangiocarcinoma, is often diagnosed at an advanced stage, making it very difficult to treat with surgery. It typically does not respond to chemotherapy and fewer that one in twenty patients will survive for five years after diagnosis.

Professor Stuart Forbes from the MRC Centre for Regenerative Medicine at the University of Edinburgh, said: “We are excited by these results because these drugs are already being tested in clinical trials for other types of cancer and could be beneficial for patients with cholangiocarcinoma.”
 
Dr Luke Boulter from the MRC Human Genetics Unit at the University of Edinburgh, said: “Identifying the signals that control bile duct cancer’s growth will allow us to design better treatments that are urgently needed.”
 
Helen Moremont, chairman trustee of AMMF, The Cholangiocarcinoma Charity, said: “This is potentially very exciting. Cholangiocarcinoma is an under-researched, much neglected but truly devastating disease, so it is good to see progress being made in novel areas.  We are hopeful that this research work with wnt will provide a real step forward towards a clinical trial and some long awaited possible improvements in treatment.”  

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.